Scarica l'app Stockscreener
9.39
0.63%
-0.06
Dopo l'orario di chiusura:
9.39
Precedente Chiudi:
$9.45
Aprire:
$9.39
Volume 24 ore:
2.83M
Relative Volume:
1.03
Capitalizzazione di mercato:
$2.10B
Reddito:
$509.86M
Utile/perdita netta:
$165.35M
Rapporto P/E:
13.85
EPS:
0.6779
Flusso di cassa netto:
$107.55M
1 W Prestazione:
-1.98%
1M Prestazione:
-3.69%
6M Prestazione:
-40.68%
1 anno Prestazione:
-40.42%
Intervallo 1D:
$9.33
$9.50
Intervallo di 1 settimana:
$9.32
$9.65
Portata 52W:
$7.2101
$20.46
Adma Biologics Inc Stock (ADMA) Company Profile
Nome
Adma Biologics Inc
Settore
Industria
Telefono
(201) 478-5552
Indirizzo
C/O ADMA BIOLOGICS, INC., RAMSEY
Compare ADMA vs VRTX, REGN, ARGX, MRNA, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ADMA
Adma Biologics Inc
|
9.39 | 2.12B | 509.86M | 165.35M | 107.55M | 0.6779 |
VRTX
Vertex Pharmaceuticals Inc
|
514.56 | 132.08B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
793.26 | 83.15B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
984.04 | 62.71B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
136.62 | 54.14B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
203.35 | 44.51B | 742.00K | -1.37B | -1.07B | -7.0731 |
Adma Biologics Inc Stock (ADMA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-21 | Iniziato | Canaccord Genuity | Buy |
| 2026-03-26 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2023-07-19 | Ripresa | Raymond James | Strong Buy |
| 2022-10-13 | Iniziato | Mizuho | Buy |
| 2021-11-11 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2021-11-09 | Iniziato | Cantor Fitzgerald | Overweight |
| 2019-06-04 | Iniziato | Jefferies | Buy |
| 2019-04-15 | Reiterato | H.C. Wainwright | Buy |
| 2019-02-07 | Ripresa | H.C. Wainwright | Buy |
| 2017-12-11 | Reiterato | Maxim Group | Buy |
| 2017-11-14 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2017-01-23 | Aggiornamento | Maxim Group | Hold → Buy |
| 2016-08-01 | Downgrade | Maxim Group | Buy → Hold |
| 2016-07-25 | Reiterato | Maxim Group | Buy |
| 2015-05-13 | Reiterato | Maxim Group | Buy |
| 2014-12-08 | Iniziato | Oppenheimer | Outperform |
| 2014-12-01 | Reiterato | Maxim Group | Buy |
Mostra tutto
Adma Biologics Inc Borsa (ADMA) Ultime notizie
Adma Biologics (ADMA) Falls More Steeply Than Broader Market: What Investors Need to Know - Yahoo Finance
ADMA: Adma Biologics Inc Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
Adma Biologics (ADMA) Is Considered a Good Investment by Brokers: Is That True? - Yahoo Finance
ADMAAdma Biologics Inc Volatility & Greeks - Finviz
ADMA Biologics Inc (ADMA) Stock Analysis: A Biotech With 76% Potential Upside - DirectorsTalk Interviews
Adma Biologics Stock Price Forecast. Should You Buy ADMA? - StockInvest.us
Adma Biologics (ADMA) Down 4.8% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
Trading Systems Reacting to (ADMA) Volatility - Stock Traders Daily
ADMA Tumbles On Slashed Outlook As Short-Seller Aftermath Meets Competitive Headwinds - stocktwits.com
ADMA Biologics: Maybe The Bears Are Right (Rating Downgrade) (NASDAQ:ADMA) - Seeking Alpha
ADMA Biologics Inc (ADMA) Stock Analysis: Exploring A Promising 82% Potential Upside - DirectorsTalk Interviews
ADMA BIOLOGICS, INC. (ADMA) SHAREHOLDER INVESTIGATION ALERT: Bernstein Liebhard Investigates Potential Breaches of Fiduciary Duty - TMX Newsfile
Law firm probes ADMA Biologics' leadership for possible breaches of fiduciary duty to shareholders - Pluang
Class action lawsuit filed against ADMA Biologics for misleading investors and undisclosed transactions - Pluang
ADMA Biologics (ADMA) After Strong Q2 Results And Reaffirmed Guidance Is It A Bargain - Sahm
Nomura Small Cap Growth Fund's ADMA Biologics Inc(ADMA) Holding History - GuruFocus
Investigation launched into ADMA Biologics for alleged revenue inflation via channel-stuffing. - Pluang
ADMA Biologics Inc (ADMA) Stock Analysis: Unpacking the 79% Potential Upside for Investors - DirectorsTalk Interviews
ADMA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Anno - The National Law Review
ADMA Biologics Inc (NASDAQ:ADMA) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat
Bank of America Corp DE Raises Holdings in ADMA Biologics Inc $ADMA - MarketBeat
Why ADMA Biologics (ADMA) Is Up 5.6% After Reaffirming 2026 Revenue Guidance And EPS Momentum - Sahm
Behavioral Patterns of ADMA and Institutional Flows - Stock Traders Daily
ADMA|ADMA Biologics Inc|Price:9.540|Chg%:+0.200 - TradingKey
STATE STREET CORP Buys ADMA Biologics Inc (ADMA) -- Shares Look 49% Undervalued on GF Value - GuruFocus
ADMA Biologics Number of Employees 2026 | Employee Count & Headcount Data - reveliolabs.com
Can Asceniv Help ADMA Stock Combat IG Market Challenges? - Yahoo Finance
ADMA Biologics Inc (ADMA) Stock Forecasts - Yahoo Finance
ADMA Biologics: The Earnings Reset Still Leaves More Upside (NASDAQ:ADMA) - Seeking Alpha
Royal Bank of Canada Buys 759,984 Shares of ADMA Biologics Inc $ADMA - MarketBeat
Janus Henderson Group PLC Trims Stock Holdings in ADMA Biologics Inc $ADMA - MarketBeat
ADMA DEADLINEFINAL REMINDER: Bronstein, Gewirtz and Grossman, LLC Reminds Stockholders of ADMA Biologics, Inc. to Contact the Firm Today! - ACCESS Newswire
ADMA Biologics, Inc. Deadline: ADMA Investors Have Opportunity to Lead ADMA Biologics, Inc. Securities Fraud Lawsuit Filed by The Rosen Law Firm - PR Newswire
Bronstein, Gewirtz & Grossman LLC Urges ADMA Biologics, - GlobeNewswire
ADMA Investors Have Opportunity to Lead ADMA Biologics, Inc. Securities Fraud Lawsuit with SBS Law - Business Wire
CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds ADMA Biologics Investors of Securities Class Action Lawsuit Deadline on August 10, 2026 - Voice of Alexandria
ADMA Biologics, Inc. Notice of August 10, 2026 Application Deadline for Class Action LawsuitContact Reed Kathrein at Hagens Berman Sobol Shapiro LLP By Application Deadline - PR Newswire
ADMA Biologics Inc (ADMA): Investor Outlook Highlights 71.72% Potential Upside - DirectorsTalk Interviews
Robbins LLP Reminds ADMA Investors of the August 10, 2026 Lead Plaintiff Deadline; Contact the Firm for Information About Recovering Your Losses - PR Newswire
ADMA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announc - The National Law Review
DEADLINE NEXT WEEK: Hagens Berman Advises ADMA Biologics, Inc. Investors to Contact the Firm Before August 10, 2026 - PR Newswire
BTU IMPORTANT DEADLINE: ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Peabody Energy Corporation Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – BTU - GlobeNewswire Inc.
ADMA DEADLINE REMINDER: Bronstein, Gewirtz & Grossman LLC Alerts ADMA Biologics, Inc. Investors to Participate in the Class Action Lawsuit Today - ACCESS Newswire
ADMA Biologics 48 Hour Deadline Alert: Kahn Swick & Foti, LLC Rem - The National Law Review
ADMA SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Reminds ADMA Biolog - The National Law Review
ADMA Biologics 48 Hour Deadline Alert: Kahn Swick & Foti, LLC Reminds Investors With Losses In Excess Of $100,000 of Deadline in Class Action Lawsuit Against ADMA Biologics, Inc.ADMA - ACCESS Newswire
ADMA SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Reminds ADMA Biologics Investors of Securities Class Action Lawsuit Deadline on August 10, 2026 - accessnewswire.com
ADMA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that ADMA Biologics, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
ADMA Biologics 72 Hour Deadline Alert: Kahn Swick & Foti, LLC Reminds Investors With Losses In Excess Of $100,000 of Deadline in Class Action Lawsuit Against ADMA Biologics, Inc.ADMA - businesswire.com
ADMA UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds ADMA Biologi - The National Law Review
ADMA 3-DAY DEADLINE ALERT: ADMA Biologics, Inc. Investors - GlobeNewswire
Adma Biologics Inc Azioni (ADMA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.04%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):